Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600496 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 4
- Study locations
NCT00600496: Active Phase 1 study of Breast Cancer and Lung Cancer, sponsored by AstraZeneca.
NCT00600496 is a Phase 1 study of Breast Cancer and Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 140 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600496, a Phase 1 study of Breast Cancer and Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies
Primary Outcome
Incidence and intensity of adverse events as graded by CTCAE (version 3.0), physical examinations, vital signs (including weight, blood pressure and pulse rate), ECG parameters, MUGA scan and echocardiography, clinical chemistry (including liver function tests), Brain Natriuretic Peptide (BNP), Troponin I, hematology, urinalysis, and ophthalmologic examinations.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Dacarbazine
- DRUG Temsirolimus
- DRUG Erlotinib
- DRUG AZD6244
Study Locations (4)
Michigan
- Research Site - Detroit
Pennsylvania
- Research Site - Philadelphia
Tennessee
- Research Site - Nashville
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2007-12-14 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What the registry record for NCT00600496 still lists
NCT00600496 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 8 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT00600496 reports a single indexed study location in Michigan, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00600496 about?
NCT00600496 is a clinical study titled "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)". This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies ...
What is the current status of trial NCT00600496?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2007-12-14. Estimated completion is 2025-12-31.
What conditions does trial NCT00600496 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Melanoma, Colon Cancer, Breast Neoplasms.
What interventions are being tested in trial NCT00600496?
The interventions under investigation include: Docetaxel (DRUG), Dacarbazine (DRUG), Temsirolimus (DRUG), Erlotinib (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00600496?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00600496 being conducted?
This trial has 4 study locations across Michigan, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00600496's enrollment target sits among peer trials
140 464th of 1224 higher than 757 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI